Why the study?
Globally significant variation exists in heart valve disease treatment and course, and outcome measurement remains procedure focused rather than patient focused.
The development of the ICHOM standard dataset provides a globally standardized, patient-centered framework for reporting outcomes in heart valve disease.
Establishes global standard for patient-centered valve outcomes; extends device-centric metrics to enable consistent reporting and comparative research.
BACKGROUND: Globally significant variation in treatment and course of heart valve disease (HVD) exists, and outcome measurement is procedure focused instead of patient focused. This article describes the development of a patient-related (International Consortium for Health Outcomes Measurement) standard set of outcomes and case mix to be measured in patients with HVD. METHODS: A multisociety working group was formed that included patient representatives and representatives from scientific cardiology and cardiothoracic surgery societies that publish current guidelines for HVD. The standard set was developed to monitor the patient's journey from diagnosis to treatment with either a surgical or transcatheter procedure. Candidate clinical and patient-reported outcome measures (PROMs) and case mix were identified through benchmark analyses and systematic reviews. Using an online modified Delphi process, the working group voted on final outcomes/case mix and corresponding definition. RESULTS: Patients with aortic/mitral/tricuspid valve disease or root/ascending aorta >40 mm were included in the standard set. Patients entered the dataset when the diagnosis of HVD was established, allowing outcome measurement in the preprocedural, periprocedural, and postprocedural phases of patients' lives. The working group defined 5 outcome domains: vital status, patient-reported outcomes, progression of disease, cardiac function and durability, and complications of treatment. Subsequently, 16 outcome measures, including 2 patient-reported outcomes, were selected to be tracked in patients with HVD. Case-mix variables included demographic factors, demographic variables, echocardiographic variables, heart catheterization variables, and specific details on aortic/mitral/tricuspid valves and their specific interventions. CONCLUSIONS: Through a unique collaborative effort between patients and cardiology and cardiothoracic surgery societies, a standard set of measures for HVD was developed. This dataset focuses on outcome measurement regardless of treatment, moving from procedure- to patient-centered outcomes. Implementation of this dataset will facilitate global standardization of outcome measurement, allow meaningful comparison between health care systems and evaluation of clinical practice guidelines, and eventually improve patient care for those experiencing HVD worldwide.
No takes yet. Share an insight, caveat, or question.
Lansac et al. (2025) studied Heart Valve Disease. ICHOM Standard Dataset was evaluated. A multisociety working group developed the first ICHOM standard dataset for heart valve disease, defining 16 outcome measures and 171 case-mix variables to shift focus from device- to patient-centered outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: